Literature DB >> 16396660

Migraine with and without aura: association with depression and anxiety disorder in a population-based study. The HUNT Study.

K J Oedegaard1, D Neckelmann, A Mykletun, A A Dahl, J A Zwart, K Hagen, O B Fasmer.   

Abstract

Some data indicate that migraine with aura (MA) is more strongly associated with anxiety disorder and depression than migraine without aura (MoA), but the evidence is not conclusive. In the Nord-Trøndelag Health study 1995-1997, a total of 49 205 (75% of the participants) subjects gave valid answers to both HADS (Hospital Anxiety and Depression Scale) and a validated headache questionnaire. Associations between anxiety disorder/depression and MA/MoA were evaluated by multiple logistic regression analysis. Depression (DEP) [odds ratio (OR) 1.7; 95% confidence interval (CI) 1.2, 2.6] and depression with comorbid anxiety disorder (COM) (OR 1.6; 95% CI 1.2, 2.1) were more likely in women having MA than in those with MoA. No stronger association was found for pure anxiety disorder (ANX) in MA vs. MoA (OR 0.9; 95% CI 0.7, 1.5). Among men, we found no difference in prevalence of depression and anxiety disorders between MA and MoA. This is a new finding that might have relevance for both research and clinical treatment.

Entities:  

Mesh:

Year:  2006        PMID: 16396660     DOI: 10.1111/j.1468-2982.2005.00974.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  33 in total

Review 1.  Migraine and depression: common pathogenetic and therapeutic ground?

Authors:  F Moschiano; D D'Amico; I Canavero; I Pan; G Micieli; G Bussone
Journal:  Neurol Sci       Date:  2011-05       Impact factor: 3.307

Review 2.  Migraine-associated risks and comorbidity.

Authors:  H C Diener; M Küper; T Kurth
Journal:  J Neurol       Date:  2008-09-30       Impact factor: 4.849

3.  Shared genetic factors in migraine and depression: evidence from a genetic isolate.

Authors:  A H Stam; B de Vries; A C J W Janssens; K R J Vanmolkot; Y S Aulchenko; P Henneman; B A Oostra; R R Frants; A M J M van den Maagdenberg; M D Ferrari; C M van Duijn; G M Terwindt
Journal:  Neurology       Date:  2010-01-13       Impact factor: 9.910

4.  Migraine, depression, and brain volume: the AGES-Reykjavik Study.

Authors:  Larus S Gudmundsson; Ann I Scher; Sigurdur Sigurdsson; Mirjam I Geerlings; Jean-Sebastien Vidal; Gudny Eiriksdottir; Melissa I Garcia; Tamara B Harris; Olafur Kjartansson; Thor Aspelund; Mark A van Buchem; Vilmundur Gudnason; Lenore J Launer
Journal:  Neurology       Date:  2013-05-22       Impact factor: 9.910

5.  Are sleep difficulties associated with migraine attributable to anxiety and depression?

Authors:  Angeliki Vgontzas; Lihong Cui; Kathleen R Merikangas
Journal:  Headache       Date:  2008-07-01       Impact factor: 5.887

Review 6.  [Current diagnosis and treatment of migraine].

Authors:  H-C Diener; Z Katsarava; V Limmroth
Journal:  Schmerz       Date:  2008-02       Impact factor: 1.107

7.  Behavior in the open field predicts the number of KCl-induced cortical spreading depressions in rats.

Authors:  Volodymyr Borysovych Bogdanov; Olena Viktorivna Bogdanova; Stanislav Vladimirovich Koulchitsky; Virginie Chauvel; Sylvie Multon; Mykola Yukhymovych Makarchuk; Kevin Christopher Brennan; Perry Franklin Renshaw; Jean Schoenen
Journal:  Behav Brain Res       Date:  2012-08-14       Impact factor: 3.332

8.  [Headache and migraine].

Authors:  H C Diener; M A Slomke; V Limmroth
Journal:  Nervenarzt       Date:  2007-09       Impact factor: 1.214

9.  Motor Activity in Adult Patients with Attention Deficit Hyperactivity Disorder.

Authors:  Ole Bernt Fasmer; Kristin Mjeldheim; Wenche Førland; Anita L Hansen; Steven Dilsaver; Ketil J Oedegaard; Jan Øystein Berle
Journal:  Psychiatry Investig       Date:  2014-09-30       Impact factor: 2.505

Review 10.  Migraine and psychiatric disorders: comorbidities, mechanisms, and clinical applications.

Authors:  S M Baskin; Todd A Smitherman
Journal:  Neurol Sci       Date:  2009-05       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.